GlassScriptPhysician profile
Michael G Guignon
NPI 1942542931
$3,262.19
in general payments reported to CMS, 2019-2025
21 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.62 · 2020: $325 · 2021: $378 · 2022: $152 · 2023: $336 · 2024: $1,804 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $716.26 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $701.01 | 2021-2025 | |
| Lilly USA, LLC | $407.34 | 2020-2025 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $380.28 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $224.72 | 2020-2025 | Airsupra, Farxiga |
| Pfizer INC. | $213.10 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $144.28 | 2020-2024 | Spravato |
| Allergan, INC. | $67.58 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.09 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $55.13 | 2024 | Veozah |
| Lexicon Pharmaceuticals, INC. | $42.75 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $39.66 | 2020-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.88 | 2020-2024 | Xifaxan |
| Axsome Therapeutics, INC. | $28.58 | 2024 | Auvelity |
| Edwards Lifesciences Corporation | $27.15 | 2025 | Sapien 3 Ultra Resilia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $23.56 | 2021 | |
| Radius Health, INC. | $23.42 | 2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $22.41 | 2020 | |
| Exact Sciences Corporation | $21.33 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $18.73 | 2024 | Repatha, Otezla |
| Aimmune Therapeutics, INC. | $14.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Guignon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.